CLOSEOUT LETTER
Sterling USA Nutraceuticals Lab, LLC
- Recipient:
- Sterling USA Nutraceuticals Lab, LLC
United States
- Issuing Office:
United States
| |
Los Angeles District 19701 Fairchild Road Los Angeles, CA 92612 |
February 24, 2017
Mr. Fahim Rahman
Marketing Director and Co-Owner
Sterling USA Nutraceuticals Lab, LLC
6739 San Fernando Rd.
Glendale, CA 91201-1704
Dear Mr. Rahman:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter, WL 06-13, dated November 16, 2012. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve the firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects the firm to maintain compliance and will continue to monitor their state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CDR Steven E. Porter, Jr.
Los Angeles District Director